Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Mar;19(3):343–352. doi: 10.1111/j.1365-2125.1985.tb02653.x

Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina.

A P Rae, J M Beattie, T D Lawrie, I Hutton
PMCID: PMC1463744  PMID: 3885985

Abstract

A randomised double-blind parallel group study was performed to compare the clinical efficacy of bepridil, a new calcium slow channel blocker, with that of propranolol and placebo in patients with chronic stable angina of effort. Efficacy was assessed objectively by dynamic exercise testing using an upright bicycle ergometer and subjectively by patient documentation of anginal frequency and nitrate consumption. The administration of bepridil resulted in a significant improvement in physical work capacity expressed as calculated maximal oxygen uptake (Vo2 max) and exercise time. This was associated with subjective improvement in terms of reduced anginal frequency. Despite baseline differences in exercise performance and anginal frequency between the three treatment groups, the beneficial effects of bepridil were statistically significant when compared to propranolol. Although minor electrocardiographic changes were noted, no adverse effects were evident when bepridil was prescribed in doses of up to 400 mg/day over a 10 week period.

Full text

PDF
343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaughard M., Ferrier M., Labrid C., Lamar J. C., Leboeuf J., Piris P. Studies on the bradycardia induced by bepridil. Br J Pharmacol. 1982 Feb;75(2):293–300. doi: 10.1111/j.1476-5381.1982.tb08785.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blomqvist C. G. Exercise testing in rheumatic heart disease. Cardiovasc Clin. 1973;5(2):267–287. [PubMed] [Google Scholar]
  3. Boucher M., Duchene-Marullaz D. Comparative effects of amiodarone, perhexiline and bepridil on the cardiac rhythms of the unanesthetized dog in chronic heart block. Arch Int Pharmacodyn Ther. 1978 May;233(1):65–75. [PubMed] [Google Scholar]
  4. Canicave J. C., Deu J., Jacq J., Paillet R. Un nouvel antiangoreux, le bépridil. Appréciation de son efficacité par l'épreuve d'effort au cours d'un assai à double insu contre placebo. Therapie. 1980 Sep-Oct;35(5):607–612. [PubMed] [Google Scholar]
  5. Cosnier D., Duchenne-Marullaz P., Rispat G., Streichenberger G. Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):133–151. [PubMed] [Google Scholar]
  6. Davies C. T., Sargeant A. J. Effects of training on the physiological responses to one- and two-leg work. J Appl Physiol. 1975 Mar;38(3):377–375. doi: 10.1152/jappl.1975.38.3.377. [DOI] [PubMed] [Google Scholar]
  7. Desoutter P., Haiat R. Modification électrocardiographiques induites par le bépridil. Un nouvel inhibiteur calcique. Arch Mal Coeur Vaiss. 1980 Oct;73(10):1237–1238. [PubMed] [Google Scholar]
  8. Gobel F. L., Norstrom L. A., Nelson R. R., Jorgensen C. R., Wang Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation. 1978 Mar;57(3):549–556. doi: 10.1161/01.cir.57.3.549. [DOI] [PubMed] [Google Scholar]
  9. Greenblatt D. J., Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1):118–129. doi: 10.2165/00003495-197407010-00008. [DOI] [PubMed] [Google Scholar]
  10. Harder D. R., Sperelakis N. Bepridil blockade of Ca2+-dependent action potentials in vascular smooth muscle of dog coronary artery. J Cardiovasc Pharmacol. 1981 Jul-Aug;3(4):906–914. doi: 10.1097/00005344-198107000-00024. [DOI] [PubMed] [Google Scholar]
  11. Kane K. A., Winslow E. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil. J Cardiovasc Pharmacol. 1980;2(2):193–203. doi: 10.1097/00005344-198003000-00010. [DOI] [PubMed] [Google Scholar]
  12. Marshall R. J., Muir A. W. The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs. Br J Pharmacol. 1981 Jun;73(2):471–479. doi: 10.1111/j.1476-5381.1981.tb10445.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McDevitt D. G. Adrenoceptor blocking drugs: clinical pharmacology and therapeutic use. Drugs. 1979 Apr;17(4):267–288. doi: 10.2165/00003495-197917040-00002. [DOI] [PubMed] [Google Scholar]
  14. McGraw B. F., Hemberger J. A., Smith A. L., Schroeder J. S. Variability of exercise performance during long-term placebo treatment. Clin Pharmacol Ther. 1981 Sep;30(3):321–327. doi: 10.1038/clpt.1981.167. [DOI] [PubMed] [Google Scholar]
  15. Merillon J. P., Duffloux M. A., Eustigneff T., Pansard Y., Guiomard A., Zygelman M., Aumont M. C., Gourgon R. Modifications hémodynamiques et coronaires induites par différents inhibiteurs des canaux lents dans l'insuffisance coronaire chronique: la nifédipine, le vérapamil et le bépridil. Therapie. 1981 Mar-Apr;36(2):123–134. [PubMed] [Google Scholar]
  16. Packer M., Meller J., Medina N., Yushak M., Smith H., Holt J., Guererro J., Todd G. D., McAllister R. G., Jr, Gorlin R. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation. 1982 Apr;65(4):660–668. doi: 10.1161/01.cir.65.4.660. [DOI] [PubMed] [Google Scholar]
  17. Robinson B. F. Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation. 1967 Jun;35(6):1073–1083. doi: 10.1161/01.cir.35.6.1073. [DOI] [PubMed] [Google Scholar]
  18. Singh B. N., Nademanee K., Baky S. H. Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs. 1983 Feb;25(2):125–153. doi: 10.2165/00003495-198325020-00003. [DOI] [PubMed] [Google Scholar]
  19. Tweddel A. C., Beattie J. M., Murray R. G., Hutton I. The combination of nifedipine and propranolol in the management of patients with angina pectoris. Br J Clin Pharmacol. 1981 Aug;12(2):229–233. doi: 10.1111/j.1365-2125.1981.tb01205.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Vogel S., Crampton R., Sperelakis N. Blockade of myocardial slow channels by bepridil (CERM-1978). J Pharmacol Exp Ther. 1979 Sep;210(3):378–385. [PubMed] [Google Scholar]
  21. Winslow E., Kane K. A. Supraventricular antidysrhythmic and electrophysiological effects of bepridil, a new antianginal agent. J Cardiovasc Pharmacol. 1981 Jul-Aug;3(4):655–667. doi: 10.1097/00005344-198107000-00001. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES